Bifogade filer
UK CMD 2023 EN
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
CRAWLEY, UK – Elekta (EKTA-B.ST) CEO, Gustaf Salford, was joined by several executive managers and key leaders to provide an update on Elekta’s market development and progress on the company’s strategy, ACCESS 2025. The presentation was delivered during a Capital Markets Day at Elekta’s office in Crawley, UK on June 20.
Gustaf Salford noted how the increasing cancer burden, combined with a shortage of trained clinicians, has increased the need for and value of Elekta’s solutions. “We now look forward to entering the second half of ACCESS 2025 with good momentum to focus on value creation. Value for our customers, value for the patients they treat, and value for our shareholders.”
Elekta’s President of Linac and Software Solutions, Maurits Wolleswinkel, described the innovation funnel, in particular the recently launched Elekta ONE software suite, designed to increase productivity while managing clinicians’ need for more complex workflows and personalized care. “We have launched several innovations the past two years and we are now bringing online adaptive across all our solutions to increase value and patient outcomes,” he said.
Tobias Hägglöv, CFO, presented an overview of the current financial status, Elekta’s outlook and how to achieve it. ”I look forward to utilizing current momentum to drive growth and margin expansion ahead, in line with our guidance to 2024/25,” he said.
Hilma Nordquist, Group Sustainability Director, explained how Elekta’s current strategy and long-term development will be delivered sustainably. “We will rely on hypofractionation and advanced technology, to consume less energy while enabling better outcomes and higher productivity.”
Dr. Alison Tree, the Clinical Steering Committee Chair of the international MR-Linac Consortium, as well as a clinical oncologist investigating the benefits of profoundly hypofractionated radiotherapy at The Royal Marsden NHS Foundation Trust, also spoke about the great progress that has been made using Unity and the outcomes to date.
Other speakers included Elekta’s regional heads as well as those responsible for software and commercial activities.
# # #
For further information, please contact:
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: mattias.thorsson@elekta.com
Time zone: CET: Central European Time
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.